Related Experiment Videos
Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects
Angela Vidal-Jordana1, Xavier Montalban1
1Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Ps Vall d'Hebron 119-129, Barcelona 08035, Spain.
Abstract:
Multiple sclerosis (MS) is a chronic autoimmune and degenerative disease of the central nervous system that affects young people. MS develops in genetically susceptible individuals exposed to different unknown triggering factors. Different phenotypes are described. About 15% of patients present with a primary progressive course and 85% with a relapsing-remitting course. An increasing number of disease-modifying treatments has emerged. Although encouraging, the number of drugs challenges the neurologist because each treatment has its own risk-benefit profile. Patients should be involved in the decision-making process to ensure good treatment and safety monitoring adherence.
Insights
Multiple sclerosis (MS) is a chronic autoimmune central nervous system disease affecting young adults. Optimal management involves patient-doctor collaboration due to diverse treatment options and individual risk-benefit profiles.
Area of Science:
- Neurology
- Immunology
- Genetics
Background:
- Multiple sclerosis (MS) is a chronic, autoimmune, and degenerative central nervous system disease primarily affecting young individuals.
- MS pathogenesis involves genetic susceptibility and unknown environmental triggers, leading to varied clinical presentations.
- The disease commonly manifests as relapsing-remitting (85%) or primary progressive (15%) courses.
Purpose of the Study:
- To review the current landscape of disease-modifying treatments for multiple sclerosis.
- To highlight the challenges faced by neurologists in selecting appropriate treatments based on individual risk-benefit profiles.
- To emphasize the importance of patient involvement in treatment decisions for adherence and safety.
Main Methods:
- Literature review of current multiple sclerosis phenotypes and disease-modifying therapies.
- Analysis of treatment selection criteria, including risk-benefit assessments.
- Discussion of patient-centered care models in managing chronic neurological conditions.
Main Results:
- An expanding array of disease-modifying treatments is available for multiple sclerosis.
- Each treatment option presents a unique risk-benefit profile, complicating clinical decision-making.
- Patient engagement in the decision-making process is crucial for treatment adherence and safety.
Conclusions:
- Effective management of multiple sclerosis requires careful consideration of diverse treatment options.
- Shared decision-making between patients and neurologists is essential for optimizing therapeutic outcomes and monitoring.
- Personalized treatment strategies are key to managing the complexities of multiple sclerosis.